PARG and prostate cancer: If this scenario also holds true in prostate cancer, our study may warrant further investigation of whether BTF3 silencing-induced DNA replication vulnerability sensitizes cells to PARG inhibition, a potential new treatment strategy that can be extended to treat prostate cancer patients.